## Funding Opportunities in Cancer Research

**Opportunities specific to early career applicants are noted in green below.**

<table>
<thead>
<tr>
<th>Deadline</th>
<th>Funding Opportunity</th>
<th>Sponsor</th>
<th>Max Amount and Period</th>
<th>RFP Snapshot Description</th>
<th>Eligibility Notes</th>
<th>Applicant Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LETTER OF INTENT:</strong> March 4, 2024 - Noon CST</td>
<td>AACR Gertrude B. Elion Cancer Research Award</td>
<td>AACR</td>
<td>$225,000 for 1 year</td>
<td>This is a joint effort between GlaxoSmithKline and AACR to encourage and support tenure-eligible junior faculty. The research proposed for funding must focus on cancer etiology, diagnosis, treatment, or prevention and may be basic, translational, or clinical in nature.</td>
<td>Applicants must have a doctoral degree in a related field and not currently be a candidate for a further doctoral degree. They must hold a tenure-eligible position at the rank of Assistant Professor. Applicants cannot be tenured or under consideration for a tenure academic position at the time of application. Applicants must have completed their most recent doctoral degree with the past 11 years. Applicants must also be active AACR members in good standing. Nonmembers can apply for membership online.</td>
<td></td>
</tr>
<tr>
<td><strong>LETTER OF INTENT:</strong> March 12, 2024 - Noon CST</td>
<td>The Mark Foundation Endeavor Awards</td>
<td>The Mark Foundation</td>
<td>$3M over 3 years</td>
<td>The Mark Foundation Endeavor Awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts.</td>
<td>Applicants must have an independent faculty research appointment (tenure-track or equivalent) at a non-profit academic institution. There are no citizenship requirements. Applicant teams must be composed of one PI and between 2 and 8 co-PIs. Inter-institutional collaborations are permitted and encouraged. Teams are encouraged to consider diversity in terms of discipline, seniority, gender, race, ethnicity, and any other parameters that will enhance the team’s ability to approach challenging problems from fresh perspectives.</td>
<td></td>
</tr>
<tr>
<td><strong>LETTER OF INTENT:</strong> March 15, 2024 - 4PM CST</td>
<td>INTERNAL: Siteman Investment Program Research Development Awards, 2024 Cycle 1 (SIP RDA)</td>
<td>Siteman Cancer Center</td>
<td>Varies by mechanism from $50,000 to $800,000 over 1-3 years</td>
<td>The SIP RDA is designed to award development funding to faculty investigators to support pioneering cancer research and produce data to leverage further external peer-reviewed funding. Available mechanisms include: New and Established Clinical Trials, Phase 01 Brain Tumor Center (BTC) Clinical Trials, Pre-R01, Pre-R01 for Collaborations with University of Missouri-Columbia, Team Science, and COE Supplement.</td>
<td>The PI must have a full-time faculty appointment at Washington University (WU), Saint Louis University (SLU), or the University of Missouri-Columbia (UMC). Faculty from Saint Louis University and University of Missouri-Columbia are required to have a WU Siteman Cancer Center faculty member as co-PI. The contact PI submitting the application must be a Siteman Cancer Center member or must submit a membership application by the SIP RDA full application deadline.</td>
<td></td>
</tr>
</tbody>
</table>

---

**Click here to view the opportunities online and bookmark the Siteman "Funding for Faculty" page.**
| March 19, 2024 - 2PM CST | NEW: Harold Amos Medical Faculty Development Program (AMPDP) | Robert Wood Johnson Foundation | $420,000 over 4 years | The Harold Amos Medical Faculty Development Program (AMPDP) offers four-year postdoctoral research awards to faculty from historically marginalized backgrounds who can achieve senior rank in academic medicine, dentistry, or nursing. This program supports the development of faculty to enhance their influence as leaders, researchers, and advisors in supporting a Culture of Health, in which everyone has the chance to live the healthiest life possible. Applicants must be from historically marginalized backgrounds and be able to describe how their background, identity, or lived experiences have positioned them to contribute in the goals of the program. Examples of marginalized backgrounds include, but are not limited to, first-generation college graduates; individuals from lower socioeconomic backgrounds; individuals from communities of color; and individuals with disabilities. All applications should be US citizens, permanent residents, or be individuals granted DACA status at the time of application. Applicants must be completing or have completed their formal clinical training and must be able to spend at least 70 percent of their time engaged in research. | Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing your proposal. |
| March 25, 2024 - 9PM CST | NEW: ALSF 2024 Reach Grant | Alex’s Lemonade Stand Foundation | $250,000 over 2 years | The Reach Grant seeks pre-clinical hypothesis-driven research projects that are necessary to move a study from the pre-clinical arena into a clinical trial. The goal of this award is to support translational studies that will result in a phase 1 and/or 2 clinical trial, two to three years from the project end date. Examples of appropriate research projects include but are not limited to, completing IND-enabling studies, providing requisite pre-clinical data for clinical trial development, or perhaps through the validation of biomarkers that will enable selection of the correct patients for entry into new clinical trials. Applicants must have an MD, PhD, MD/PhD or equivalent and have a demonstrated track record of pediatric cancer research with experience in translational research. Multiple investigator applications that bring together pairs or teams of researchers with complementary expertise are encouraged. | Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing the proposal. |
| March 31, 2024 - 9PM CST | INTERNAL: Center for Drug Discovery (QuikSTART Grant) | Center for Drug Discovery and Siteman Cancer Center | $15,000 for 1 year | This award is designed to advance the translation of new discoveries in cancer disease biology into small molecule therapeutics for the benefit of patients. CDD offers a full suite of preclinical drug discovery services and know-how. Capabilities range from drug lead finding utilizing the High Throughput Screening Core to Medicinal Chemistry-driven drug lead optimization, ADME profiling, and in-vivo pharmacokinetics, furnishing drug-like molecules for proof-of-concept in vivo pharmacology studies and intellectual property (patent) filing. The QuikSTART award is viewed as a “hand-up” to generate preliminary data to enable successful following-on funding (e.g., NCI, NIH, private foundation, commercial partnership), publication, and patent filing. The PI must have a full-time faculty appointment at Washington University (WU) at the rank of Assistant Professor or above and hold Siteman Cancer Center membership. | N/A |
| April 1, 2024 - 10:30PM CST | Discovery Boost Grant (DBG) | American Cancer Society | $270,000 over 2 years | Discovery Boost Grants (DBGs) support high-risk, high-reward exploratory cancer research across the research continuum. Investigators may focus on developing research methodologies, establishing feasibility, or leading pilot tests. It is expected that preliminary data generated from a completed DBG will have the potential to secure additional grant funding to further the research and open new and highly innovative areas for investigation. PIs must have an independent faculty appointment at a US academic institution. | Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing your proposal. |
| April 1, 2024 - 10:30PM CST | Clinician Scientist Development Grant (CSDG) | American Cancer Society | $405,000 to $675,000 over 3-5 years | The Clinician Scientist Development Grant (CSDG) supports full-time faculty members in becoming independent investigators as clinician scientists. This grant is designed for people trained primarily as clinicians who want to maintain clinical practice and conduct cancer research. Applicants must have a doctoral degree, an active clinical license, and participate in clinical care. They must not be a current or former PI of an individual member training grant. They also must not have an R-level or equivalent grant as PI. | Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing your proposal. |
STAGE 1

Mission Boost Grants (MBG) are designed to support selected current and past ACS grantees specifically for the translation of their research to human testing. MBGs are opportunities for American Cancer Society (ACS) grantees to seek additional, or "boost," resources for innovative, high-risk/high-reward projects.

PIs must have an independent faculty appointment at a US academic institution and must hold one of the following ACS grants for a minimum of 1 year:
- Research Scholar Grant (RSG)
- Clinician Scientist Development Grant (CSDG)
- Mentored Research Scholar Grant (MRSG)
- Cancer Control Career Development Award (CCDA)
- Pilot and Exploratory Projects in Palliative Care (PEP) Award
- ACS Postdoctoral Fellowship (previous fellows only)

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing your proposal.

STAGE 2

Research Scholar Grants (RSG) provide support for investigator-initiated and self-directed researchers and clinician scientists, who are investigators licensed to provide patient care and trained to conduct research. Grant proposals are investigator-initiated and may pursue questions across the cancer research continuum, as long as they fit within an American Cancer Society (ACS) priority research area.

PIs must work at a US academic institution and have been appointed as an independent, full-time faculty member less than 10 years ago. Additionally, they may not be the PI on more than one RSG or equivalent grant at the time of application.

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing your proposal.

HESI THRIVE Grant Program

The THRIVE grant program is designed to provide seed funding to investigators for the testing of initial hypotheses and collecting of preliminary data to help secure long-term funding by the National Institutes of Health and/or other major granting institutions.

Principal investigator(s) must hold an M.D., Ph.D., D.V.M., or equivalent degree. Candidates for these degrees along with their Principal Investigator may apply. All candidates must have an accredited faculty, medical institution, or other research institute appointment and have the ability to conduct independent research with publications in established peer-reviewed medical and scientific journals. This funding opportunity is open internationally. Awarders must be willing to participate in the annual HESI THRIVE research forum – an opportunity to share results and build a network of experts.

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing the proposal.

Genentech Health Equity Innovation Fund

The Genentech Health Equity Innovation Fund catalyzes powerful partnerships - often between health systems and communities - that have the potential to shift policies, mindsets, evidence base, and practices to eliminate inequities in patient health outcomes. Through transformational, multi-year funding, Innovation Fund grantees are pursuing community-driven solutions that have the power to promote lasting, widespread improvements in healthcare but have been historically under-resourced. Genentech is specifically seeking proposals that address inequities in patient outcomes and healthcare workforce experiences across several therapeutic areas, including breast, lung, and liver cancers.

Projects must be led by teams that are representative of the patients and communities (e.g., race, ethnicity, gender, sexual orientation) impacted by the proposal. The proposals should aim to tackle institutional or systemic barriers to health equity for patients, students, and communities of color, with a focus on addressing racism as a root cause.

Application Assistance: Washington University faculty may reach out to Sarah Van Vickle-Chavez in Public Health Sciences at sarahv@wustl.edu with any questions and for assistance with the proposal, including gathering pertinent catchment statistics.

Application Assistance: Washington University faculty may also reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing the proposal.
Gateway funds Phase I and II patient-centered cancer clinical trials that have the potential to shift the paradigm for standard of care. We strive to fund treatment-based studies at the bedside, including all types of cancers. At Gateway, it is always and only about the patient. Involvement of patient advocates and patient advocacy groups in the design of the clinical trial, incorporating patient-reported outcomes and quality of life tools, and including patient advocates on research study review committees, are all ways to incorporate the patient’s unique perspective into the research study.

The applicant must have the expertise and data access necessary to conduct the proposed project successfully. In general, the applicant PI will be expected to have a medical or postdoctoral degree (MD, PhD, or equivalent). Applicants with a Master's degree in a relevant field and sufficient experience will be considered. A multidisciplinary team is encouraged, and should include both clinical and methodologic expertise aligned with the proposal objectives, as well as patient partners.

The applicant must hold a PhD and/or MD (or equivalent). They must have begun their first post-training position and tenure-track (or equivalent) faculty position on or after 3/1/2020, or have accepted an offer for a tenure-track (or equivalent) position that will begin no later than 3/1/2025. Applications are encouraged from individuals of all backgrounds, including members of groups underrepresented in science and from institutions not previously affiliated with HHMI.

Other available programs include:
- NCI SPORE PI20 Program
- Integrative Research
- Society for Integrative Oncology (SIO)
- Decentralized Clinical Trial Initiative (DCTI)

When applying:
- DO, or DO/PhD and have completed their terminal degree within the past 10 years. They must also not have any substantial NIH research grants.
- Applicants must hold the degree of MD, MD/PhD, DO, or DOPhD and have completed their terminal degrees within the past 10 years. They must also not have any substantial NIH research grants.

Robert A. Winn Diversity in Clinical Trials Career Development Award

This is an early-stage investigator (ESI) proposal. Applicants must have demonstrated a commitment to increasing diversity in clinical research.

Applications are encouraged from individuals of all backgrounds, including members of groups underrepresented in science and from institutions not previously affiliated with HHMI.

Robert A. Winn Diversity in Clinical Trials Career Development Award

Agrawal provides seed funding in the US proposing research directed toward identifying new treatments or cures for cancer. The Foundation funds projects for a one-year period which will allow the establishment of capabilities of new cancer researchers or new cancer approaches by established cancer researchers. It is anticipated that this early-stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified.

Robert A. Winn Diversity in Clinical Trials Career Development Award

This award is designed to support the cancer development of early-stage investigator physicians who are underrepresented in medicine, and physicians who have demonstrated a commitment to increasing diversity in clinical research.

Applications are encouraged from individuals of all backgrounds, including members of groups underrepresented in science and from institutions not previously affiliated with HHMI.
<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Website</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCC BQSR Biostatistics and Qualitative Research Shared Resource</td>
<td>Grant Preparation Support - Free for SCC Members</td>
<td>N/A</td>
</tr>
<tr>
<td>WUSTL CCC Center for Drug Discovery</td>
<td>CDD Match Grants</td>
<td>Rolling Deadlines</td>
</tr>
<tr>
<td>WUSTL ICTS Institute of Clinical and Translational Sciences</td>
<td>Innovation Awards</td>
<td>Rolling Deadlines</td>
</tr>
<tr>
<td>WUSTL ICTS and Siteman Cancer Center</td>
<td>Just-In-Time (JIT) Core Usage Funding Program</td>
<td>Rolling Deadlines; Siteman Cancer Center will co-sponsor cancer-focused proposals.</td>
</tr>
</tbody>
</table>

**Click to view these opportunities in a web browser and bookmark the Siteman "Funding for Faculty" page.**